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The current standard to assess pentavalent antimonial (SSG)
susceptibility of Leishmania is a laborious in vitro assay of
which the result has little clinical value because SSG-resistant
parasites are also found in SSG-cured patients. Candidate
genetic markers for clinically relevant SSG-resistant parasites
identiﬁed by full genome sequencing were here validated on
a larger set of clinical strains. We show that 3 genomic loca-
tions sufﬁce to speciﬁcally detect the SSG-resistant parasites
found only in patients experiencing SSG treatment failure.
This ﬁnding allows the development of rapid assays to
monitor the emergence and spread of clinically relevant SSG-
resistant Leishmania parasites.
Leishmania is a protozoan parasite that is transmitted by sand
ﬂies and can cause cutaneous, mucocutaneous, or visceral
disease in Latin America, the Mediterranean Basin, East
Africa, and Asia. Visceral leishmaniasis (VL), thought to be
lethal if left untreated, is the systemic form of the disease and
is caused by Leishmania infantum (syn L. chagasi) and Leish-
mania donovani—the latter being responsible for VL in the
hyperendemic regions of the Indian subcontinent and East-
Africa [1]. Antimonials (SSG) have long been the ﬁrst-line
treatment for leishmaniasis throughout the world, but an in-
creasing rate of SSG treatment failure has been reported in the
Indian subcontinent [2, 3]. This was shown to be associated
among others with SSG resistance of the parasites [4, 5].
So far, the gold standard for determining the SSG susceptibil-
ity of Leishmania strains is an in vitro test in which the survival
of the intracellular form of the parasite in infected macrophages
is microscopically evaluated at various concentrations of SSG
[6]. However, this test is difﬁcult to standardize, labor-intensive,
and therefore not suitable for routine testing of a large amount
of samples (eg, for epidemiological purposes). Furthermore, the
current in vitro assays do not necessarily identify clinically rele-
vant SSG resistance phenotypes, as shown by a previous clinical
study in Nepal in which in vitro SSG-resistant L. donovani were
not only found in all SSG-nonresponder patients but also in
65.0% of the SSG-cured patients [5]. This poor accuracy might
be explained by, among others, the absence of an immunologi-
cal environment, which is known to be crucial in determining
SSG clinical outcome, in these in vitro assays and thus the pres-
ence of undetected parasite epi-phenotypes that may inﬂuence
such host-pathogen interactions.
Laboratory tools that are easier to use and able to identify
the clinically relevant SSG-resistant phenotype are thus pivotal
to correctly monitor the further dynamics of drug resistance
in natural populations. Several candidate markers at gene ex-
pression level have been proposed (reviewed elsewhere [7]),
but they have yet to be validated in a large sample or were not
uniformly present in all natural SSG-resistant strains analysed.
Here, 5 single-nucleotide polymorphisms (SNPs) selected
from a previous whole genome study [8] were tested on a
larger sample of clinical L. donovani strains from the Indian
subcontinent to evaluate their performance and predictive
value for (1) the in vitro SSG-resistant phenotype of the para-
site and (2) SSG treatment failure of the infected patient.
METHODS
Written informed consent was obtained from all patients
prior to enrolment and in the case of children from their
parents or guardians. The LeishNatDrug study in which
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the Nepalese strains (further labeled with the preﬁx BPK)
were isolated was approved by the institutional review boards
of (1) the Nepal Health Research Council, Kathmandu, Nepal,
and (2) the Institute of Tropical Medicine (ITM), Antwerp,
Belgium. The Kaladrug-R study in which the Indian strains
(further labeled with the preﬁx BHU) were isolated was ap-
proved by the institutional review boards of (1) the Faculty of
Medicine, Banaras Hindu University, Varanasi, India, and (2)
the ITM, Antwerp, Belgium.
Mouse care and experimental procedures were performed
under approval of the animal ethics committee of the Institute
of Tropical Medicine Antwerp and were in compliance with
the national and international laws for the protection and
welfare of animals.
A list of all strains, their metadata, and their World Health
Organization codes are available as supplementary data. The
BPK L. donovani strains were isolated from bone marrow aspi-
rates from 36 patients with conﬁrmed VL recruited at the
B. P. Koirala Institute of Health Sciences, Dharan, Nepal,
during the LeishNatDrug project in 2002–2003. The BHU
L. donovani strains were isolated from spleen aspirates from
14 patients with conﬁrmed VL recruited at the Kala-Azar
Medical Research Centre in Muzaffarpur, India, during the
Kaladrug-R study in 2009–2010. All but 4 of the Nepalese
BPK patients discussed here received a full supervised treat-
ment course of sodium antimony gluconate of 20 mg/kg/day
intramuscularly for 30 days and were followed-up for clinical
and parasitological evaluation at the end of treatment and at
3, 6, and 12 months after start of treatment. All sampled
Indian patients in this study received a treatment other than
sodium antimony gluconate. Initial cure was deﬁned as a VL
case with absence of fever, decreased spleen size, and negative
parasitology at the end of a full treatment course. Nonre-
sponders were cases with positive parasitology after a full
treatment course. Deﬁnite cure was deﬁned as a patient with
initial cure who showed no signs and symptoms of relapse at
the 12-month follow-up visit. Relapse was deﬁned as a patient
with initial cure but reappearance of clinical signs and positive
parasitology during follow up. Treatment failure was deﬁned
as either nonresponse or relapse [5].
The clinical isolates were cryopreserved after isolation and
sent (under controlled conditions) to ITM for backup and
monitored storage until the onset of the experiments. All iso-
lates were identiﬁed as Leishmania (Leishmania) donovani by
polymerase chain reaction restriction fragment length poly-
morphism (PCR-RFLP) analysis of cysteine proteinase b [9].
Clones were derived from isolates using the microdrop
method to obtain homogenous working parasite populations
[10]. The SSG susceptibility was evaluated in an in vitro amas-
tigote model as described elsewhere [5, 11].
Genome sequences of 17 L. donovani strains (10 SSG-
susceptible and 7 SSG-resistant) were previously screened for
homozygous SNPs occurring solely in SSG-resistant strains.
However, SSG-resistant L. donovani may have emerged on dif-
ferent genetic backgrounds, and a single SNP shared by all
SSG-resistant phenotypes in the sample was not found [8].
From the SNPs speciﬁc to the previous SSG-resistant strains, 5
were selected and here used in a multilocus sequence typing
(MLST) approach to screen the present collection of clinical
isolates (Supplementary Figure 1). SNPs were detected in
DNA isolated from promastigotes either by screening whole
genome sequencing data as described elsewhere [8] or by PCR
amplicon sequencing of the region around the SNP (primers
and conditions are available as supplementary data).
RESULTS AND DISCUSSION
Each of the 61 L. donovani strains was assigned a haplotype
determined by its base composition at the 5 selected SNPs
(haplotypes 1–8) (see Table 1). The distribution of the
Table 1. Observed Haplotypes of Leishmania donovani
Haplotype
Location
chr13 pos442924 chr24 pos26882 chr35 pos1192217 chr35 pos1619958 chr35 pos1656169
1a A C C G C
2 b T b A b
3 b C/T b A/G b
4 b C/T b b b
5 b b T b b
6 b b C/T b b
7 b b b b T
8 T b b b b
Accession codes: chromosome 13, FR799600.1; chromosome 24, FR799611.1; chromosome 35, FR799622.1.
a Haplotype 1 is considered to be the reference haplotype (L. donovani BPK282/0cl4).
b Same base as the reference.
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haplotypes was assessed in the context of (1) the in vitro SSG
susceptibility phenotype (as determined by the current in
vitro assay) and (2) the treatment outcome of the patient. All
clones showed identical haplotypes as the mother isolate from
which they were derived (the haplotypes of each individual
strain and summarizing tables are available as supplementary
data).
Assessing the haplotypes of strains with a known in vitro
SSG phenotype (20 SSG-susceptible and 29 SSG-resistant)
showed that the majority of in vitro SSG-susceptible strains
had haplotype 1 (16 of 20) whereas most SSG-resistant strains
had haplotype 1 or 2 (11 and 10 of 29, respectively) (Table 2).
The distribution of haplotypes 2–8 (taken together) and
haplotype 1 was signiﬁcantly different between in vitro
SSG-resistant and SSG-susceptible strains (Fisher exact test;
P = .0078). The presence of haplotypes 2–8 in a strain showed
a sensitivity of 62.1% (95% conﬁdence interval [CI], 42.4%–
78.7%), a speciﬁcity of 80.0% (95% CI, 55.7%–93.4%) and a
positive and negative predictive value of 81.8% (95% CI,
59.0%–94.0%) and 59.3% (95% CI, 39.0%–77.0%), respective-
ly, for in vitro SSG resistance. This low negative predictive
value is due to the high prevalence of haplotype 1 among the
SSG-resistant strains. Further screening for additional SNPs
might reveal other loci, allowing resolution of the latter SSG-
resistant strains from SSG-susceptible ones. This is consistent
with the hypothesis that SSG resistance has multiple origins
[8, 12, 13]. Alternatively, SSG-resistant strains that carried
haplotype 1 could still be phenotypically different from the
other SSG-resistant strains at an as yet uncharacterized level.
This hypothesis is supported by the fact that all haplotype 1
SSG-resistant strains were isolated from patients that were
cured with SSG. These parasites possibly represent a sub-
population of in vitro SSG-resistant parasites that lack the
epi-phenotype that allows them to survive SSG treatment
in vivo—an epi-phenotype that remains hidden in the current
in vitro test, likely due to the lack of host immune compo-
nents [5]. In this context, the haplotypes of the strains should
also be directly correlated with the SSG treatment outcome of
the patients from which they were isolated, irrespective of the
in vitro SSG phenotype of the infecting strain.
Thirty-two Nepalese patients enrolled in this study received
a full course of SSG treatment and completed the 12 month
follow-up—only strains isolated from these patients were as-
sessed in this SSG treatment outcome analysis (23 SSG deﬁ-
nite cures, 5 SSG nonresponders, and 4 SSG relapses)
(Table 2). Haplotype 1 was found in strains from 21 deﬁnite
cures and 2 relapses, and haplotypes 5 and 7 were found in
the 2 remaining strains isolated from deﬁnite cures. Haplo-
types 2, 6, and 8 occurred only in strains isolated from
patients who failed treatment (both relapses and nonrespond-
ers). The presence of haplotypes 2, 6, or 8 in a strain showed a
sensitivity of 77.8% (95% CI, 40.2%–96.1%), speciﬁcity of
100.0% (95% CI, 82.2%–100.0%), and a positive and negative
predictive value of 100.0% (95% CI, 56.1%–100.0%) and
92.0% (95% CI, 72.5%–98.6%), respectively, for SSG treatment
failure of the patient. The distribution of haplotypes 2, 6, and
8 (taken together) relative to the other haplotypes was signiﬁ-
cantly different between strains isolated from SSG treatment
failures and strains isolated from SSG deﬁnite cures (Fisher
exact test; P < .0001).
The presence of haplotypes 2, 6, or 8 in a given strain, iden-
tiﬁable by sequencing the amplicon of 3 PCR reactions, proved
to be a signiﬁcantly better marker for SSG treatment failure of
the patient compared with the previously described in vitro
deﬁned SSG-resistant phenotype of the parasite, which showed
a sensitivity of 66.7%, a speciﬁcity of 35.0%, and a positive and
negative predictive value of 31.6% and 30.0%, respectively [5].
However, testing these haplotypes on a larger number of
strains isolated from patients with well-documented SSG treat-
ment outcomes can result in a more accurate estimation of the
power and performance of these haplotypes to detect and
predict SSG treatment failure of the patient.
Several studies aimed to identify markers for in vitro SSG
resistance in clinical L. donovani isolates by targeting the thiol
metabolism of the parasite, which is important for activation
of the drug and defense against its action mechanism, and
Table 2. Frequency of Each Haplotype for In Vitro and In Vivo Phenotypes to Antimonials (SSG)
Haplotype
In Vitro SSG
Sensitivity (n = 20)
In Vitro SSG







1 16 11 21 0 2
2 2 10 0 3 1
3 1 2 0 0 0
4 0 1 0 0 0
5 0 1 1 0 0
6 1 2 0 1 1
7 0 1 1 0 0
8 0 1 0 1 0
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import/export mechanisms for the drug (reviewed elsewhere
[14]). However, these candidate markers have yet to be validat-
ed on a larger sample or were not uniformly present in all
SSG-resistant strains. This study describes the ﬁrst attempt (to
our knowledge) to validate genetic markers (MLST), earlier
identiﬁed by full genome sequencing, for clinically relevant
SSG resistance of L. donovani. It highlights the limits of the
current in vitro SSG susceptibility assays and provides a
simple and biologically more robust alternative. In this study,
just 3 PCR reactions and amplicon sequencing were sufﬁcient
to identify clinically relevant SSG resistance markers. More-
over, once these PCR reactions are optimized for use in clini-
cal samples, line-probe assays similar to those used for the
detection of drug resistance in Mycobacterium tuberculosis
[15] could be designed to simplify the application of these
markers and allow faster detection of parasites that contribute
to treatment failure. Whether in a diagnostic, epidemiological,
or experimental research setting, such a simpliﬁed format
would be easily applicable in laboratories with limited PCR
facilities.
One of the limitations of our analysis is that predictive
values depend on prevalence: the lower the prevalence, the
lower the positive predictive value of a positive result. There-
fore, the current markers should be further validated on
larger, prospective series from the Indian subcontinent and
East Africa. In the future, these markers can also be comple-
mented with new ones stemming from running genome se-
quencing projects. This MLST approach represents a
signiﬁcant asset for control programs and other epidemiologi-
cal studies aiming to monitor the emergence and spread of
clinically relevant SSG-resistant Leishmania parasites. It is also
relevant in regions where SSG was abandoned, such as in the
Indian subcontinent, to follow the disappearance (if any) of
SSG-resistant parasites and determine their impact on future
VL control strategies.
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